Induction Chemotherapy Followed by Radiotherapy Alone or Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma (IRCNPC)

  • STATUS
    Recruiting
  • End date
    Dec 21, 2024
  • participants needed
    440
  • sponsor
    Zhejiang Cancer Hospital
Updated on 25 February 2022

Summary

In this study, the investigators aim to compare the progression-free survival (PFS) and side effects of radiotherapy (RT) and concurrent chemoradiotherapy (CCRT) in locoregionally advanced nasopharyngeal carcinoma (NPC) patients with a satisfactory tumor response (complete response or partial response) after neoadjuvant chemotherapy (NACT).

Description

In this study, the investigators aim to compare the survival outcomes and side effects of radiotherapy (RT) and concurrent chemoradiotherapy (CCRT) in locoregionally advanced nasopharyngeal carcinoma (NPC) patients with a satisfactory tumor response (complete response or partial response) after neoadjuvant chemotherapy (NACT) with Docetaxel and Cisplatin treated using intensity-modulated radiotherapy (IMRT) or tomotherapy (TOMO).

Details
Condition Locally Advanced Nasopharyngeal Carcinoma
Treatment cisplatin, docetaxel, Chemotherapy, IMRT/TOMO
Clinical Study IdentifierNCT03015727
SponsorZhejiang Cancer Hospital
Last Modified on25 February 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients with newly histologically confirmed non-keratinizing carcinoma
Tumor staged as N2-3 or T3-4 (according to the 7th AJCC staging system)
No evidence of distant metastasis (M0)
Performance status: KPS>70
With normal liver function test (ALT, AST <1.5ULN)
Renal: creatinine clearance >60ml/min
Without hematopathy,marrow: WBC >4 _109/L, HGB >80G/L, and PLT>100_109/L
With controlled blood glucose for diabetes patients
Written informed consent
satisfactory tumor response (complete response or partial response) after neoadjuvant chemotherapy (NACT)

Exclusion Criteria

WHO type I squamous cell carcinoma or adenocarcinoma
Age >65 or <18
With a history of renal disease
Prior malignancy (except adequately treated carcinoma in-situ of the cervix or basal/squamous cell carcinoma of the skin)
Previous chemotherapy or radiotherapy (except non-melanomatous skin cancers outside the intended RT treatment volume)
Patient is pregnant or lactating
Peripheral neuropathy
Emotional disturbance
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note